The American College of Radiology® (ACR®) submitted comments to the Centers for Medicare and Medicaid Services (CMS) July 12 about its National Coverage Determination (NCD) for Beta Amyloid Positron Emission Tomography (PET) in Dementia and Neurodegenerative Disease.
The ACR fully supports CMS initiating this NCD analysis to determine if the current policy of one scan per patient per lifetime should be revised. The letter includes recommendations to expand access and utility of beta amyloid PET scans in clinical study protocols.
The College strongly urges CMS to expand access to gold-standard diagnostic imaging for populations most at risk for Alzheimer’s disease. CMS is expected to release its proposed decision by Dec. 16, with the final decision to be made by March 16.
If you have questions regarding this NCD reconsideration for Beta Amyloid PET in Dementia and Neurodegenerative Disease, please contact Alicia Blakey, ACR Principal Economic Policy Analyst.